GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B2248 Ketanserin4 CitationTarget: 5-HT2 ReceptorsSummary: specific 5-HT2A serotonin receptor antagonist -
B1360 Ivabradine HClSummary: Adrenergic receptor inhibitor -
B2246 Desvenlafaxine SuccinateSummary: serotonin (5-HT) transporter and norepinephrine (NE) transporter reuptake inhibitor -
B7618 XCCSummary: Adenosine receptor antagonist -
B2245 BRL-54443Summary: 5-HT1E/1F receptor agonist,potent and selective -
C5552 TetrahydromagnololSummary: peripheral CB2 receptor agonist -
B1358 Epinephrine BitartrateTarget: adrenergic receptorSummary: Adrenergic receptor agonist -
B7540 ANR 94Summary: Adenosine A2A-R antagonist -
C5513 S-2 MethanandamideSummary: potent CB1 receptor agonist -
B1357 Dexmedetomidine HClSummary: Highly selective and potent alpha-2 adrenoceptor agonist
